AUSTIN, Texas & HAMILTON, Ontario & TORONTO—Triumvira Immunologics Inc. (Triumvira), announced the upcoming presentation of key preclinical data at the American Society of Hematology (ASH) 60th Annual Meeting and Exposition, December 1-4, 2018, in San Diego, CA. The data will be presented during a poster presentation on Sunday, December 2, and a podium presentation on Monday, December 3.
“We continue to expand our knowledge base on the promise of our proprietary T cell Antigen Coupler (TAC) technology in different tumor types,” commented Andreas Bader, Ph.D., Triumvira’s Senior Vice President of R&D. “The presentations will focus on experiments using T cells genetically engineered with TACs directed against either CD19 or BCMA antigen, demonstrating robust cell-killing and anti-tumor efficacy in preclinical models of hematological malignancies with no detectable side effects.”
Podium Presentation Title:
T Cells Engineered with a Novel Chimeric Receptor Demonstrate Durable In Vivo Efficacy Against Disseminated Multiple Myeloma
Publication Number: 962; Session Name: 703. Adoptive Immunotherapy: Preclinical Studies to Improve Safety and Efficacy of CAR-T Cells; Presentation Date/Time: Monday, December 3, 2018: 4:30 – 6:00 PM PST
Presenter: Ksenia Bezverbnaya, McMaster University
T Cells Engineered with T Cell Antigen Coupler (TAC) Receptors for Haematological Malignancies
Publication Number: 3267; Session Name: 653. Myeloma: Therapy, excluding Transplantation: Poster II; Presentation Date/Time: Sunday, December 2, 2018: 6:00 PM – 8:00 PM PST
Presenter: Dr. Christopher Helsen, Director of Research & Development, and Head of Platform Development, Triumvira Immunologics.
About Triumvira Immunologics
Triumvira Immunologics, Inc. is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., a niche life-sciences investment bank, with the vision of developing novel T cell therapies that are safer and more efficacious than current cell therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with either solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, our corporate offices are located in Austin, Texas, and our research facilities are in Hamilton, Ontario. For more information, visit www.triumvira.com or send email inquiries to firstname.lastname@example.org
Phone: +1-617-374-8800, Ext. 109